BCL2 and cancer: BH3-mimetic compounds, like venetoclax, disrupt the binding between Bcl-2 and pro-apoptotic BH3-only proteins, thereby triggering apoptotic cell death in cancer cells that depend on Bcl-2's function at the mitochondria for their survival6,7.